The Pericarditis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pericarditis: An Overview
The term “pericarditis” refers to inflammation of the pericardial sac and represents the most common pathological process involving the pericardium. It may be further classified into acute pericarditis, incipient/subacute pericarditis, chronic pericarditis, and recurrent pericarditis.
As per the American Academy of Family Physicians, Acute pericarditis, inflammation of the pericardium, is found in approximately 5% of patients admitted to the emergency department for chest pain unrelated to acute myocardial infarction. It occurs most often in men 20–50 years of age.
The mainstay of treatment of pericarditis is represented by anti-inflammatory drugs. Anti-inflammatory treatments vary; however, in both effectiveness and side-effect profiles.
Pericarditis Market Key Facts
As quoted in a study by Imazio et al. titled, “Evaluation and Treatment of Pericarditis A Systematic Review”, tuberculosis is a major cause of pericarditis in developing countries but accounts for less than 5% of cases in developed countries, where idiopathic, presumed viral causes are responsible for 80–90% of cases.
“2015 ESC Guidelines for the diagnosis and management of pericardial diseases” by Adler et al. specified that men ages 16–65 years were at higher risk for pericarditis than women in the general admitted population, with the highest risk difference among young adults compared with the overall population.
According to DelveInsight’s analysis, males are affected more as compared to females, in the case of Pericarditis.
Pericarditis market size is anticipated to increase during the study period owing to the rising incident population of pericarditis in the 7MM. The expected launch of emerging therapies will also fuel the market growth.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Pericarditis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Pericarditis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
The epidemiology section provides insights into the historical and current Pericarditis Epidemiology trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.
Pericarditis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pericarditis market or expected to get launched during the study period. The analysis covers Pericarditis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pericarditis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/pericarditis-market
Pericarditis Therapeutics Analysis
Novel treatment options, along with increasing awareness regarding Pericarditis are expected to drive the growth of the Pericarditis therapeutics market.
Prominent players including Kiniska Pharmaceuticals and others are involved in developing therapies for Recurrent Pericarditis.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/pericarditis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pericarditis Competitive Intelligence Analysis
4. Pericarditis Market Overview at a Glance
5. Pericarditis Disease Background and Overview
6. Pericarditis Patient Journey
7. Pericarditis Epidemiology and Patient Population
8. Pericarditis Treatment Algorithm, Current Treatment, and Medical Practices
9. Pericarditis Unmet Needs
10. Key Endpoints of Pericarditis Treatment
11. Pericarditis Marketed Products
12. Pericarditis Emerging Therapies
13. Pericarditis Seven Major Market Analysis
14. Attribute Analysis
15. Pericarditis Market Outlook (7 major markets)
16. Pericarditis Access and Reimbursement Overview
17. KOL Views on the Pericarditis Market.
18. Pericarditis Market Drivers
19. Pericarditis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/pericarditis-market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
The Dysautonomia (Autonomic Dysfunction) Market is set to evolve in the coming years owing to the rising awareness of the disease, the launch of emerging therapies, and the incremental healthcare spending across the world. Some of the key companies such as Celltex Therapeutics, Theravance Biopharma, PTC Therapeutics, among others are diligently working in the Dysautonomia (Autonomic Dysfunction) Market.
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States